Drug Profile


Alternative Names: MM-121; SAR-256212

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Developer Merrimack Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase I Gynaecological cancer; Solid tumours

Most Recent Events

  • 09 Aug 2017 Merrimack plans the phase II SHERBOC trial for Breast cancer (Combination therapy, Metastatic disease, Second-line or greater therapy, Late-stage disease) (NCT03241810)
  • 06 Jul 2016 Seribantumab receives Fast Track designation for Non-small cell lung cancer [IV,Infusion] (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
  • 17 May 2016 Efficacy data from a phase II trial in Breast cancer (Combination therapy, Late-stage disease) released by Merrimack ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top